abstract |
The present invention relates to a cyclic peptidomimetic compound as a therapeutic agent capable of inhibiting a predetermined cell death 1 (PD1) signaling pathway. The invention also relates to derivatives of therapeutic agents. The present invention also encompasses the use of said therapeutic agents and derivatives for the treatment of disorders via immune enhancement, including suppression of the immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapeutic therapies therewith do. |